" /> Risankizumab - CISMeF





Preferred Label : Risankizumab;

NCIt synonyms : Risankizumab-rzaa;

NCIt definition : A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.;

UNII : 90ZX3Q3FR7;

CAS number : 1612838-76-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1612838-76-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Skyrizi;

Molecule name : ABBV-066; BI-655066;

NCI Metathesaurus CUI : CL773300;

Details


You can consult :


Nous contacter.
22/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.